Ramucirumab
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
|
TITLE
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
Overview
Ramucirumab is a monoclonal antibody that is FDA approved for the treatment of advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy and metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. There is a Black Box Warning for this drug as shown here. Common adverse reactions include hypertension and diarrhea.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Ramucirumab FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Ramucirumab in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Ramucirumab in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Ramucirumab FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Ramucirumab in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Ramucirumab in pediatric patients.
Contraindications
There is limited information regarding Ramucirumab Contraindications in the drug label.
Warnings
|
TITLE
See full prescribing information for complete Boxed Warning.
Condition Name: (Content)
|
There is limited information regarding Ramucirumab Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Ramucirumab Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Ramucirumab Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Ramucirumab Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Ramucirumab in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ramucirumab in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Ramucirumab during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Ramucirumab in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Ramucirumab in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Ramucirumab in geriatric settings.
Gender
There is no FDA guidance on the use of Ramucirumab with respect to specific gender populations.
Race
There is no FDA guidance on the use of Ramucirumab with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Ramucirumab in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Ramucirumab in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Ramucirumab in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Ramucirumab in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Ramucirumab Administration in the drug label.
Monitoring
There is limited information regarding Ramucirumab Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Ramucirumab and IV administrations.
Overdosage
There is limited information regarding Ramucirumab overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Ramucirumab Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Ramucirumab Mechanism of Action in the drug label.
Structure
There is limited information regarding Ramucirumab Structure in the drug label.
Pharmacodynamics
There is limited information regarding Ramucirumab Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Ramucirumab Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Ramucirumab Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Ramucirumab Clinical Studies in the drug label.
How Supplied
There is limited information regarding Ramucirumab How Supplied in the drug label.
Storage
There is limited information regarding Ramucirumab Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Ramucirumab |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Ramucirumab |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Ramucirumab Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Ramucirumab interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Ramucirumab Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Ramucirumab Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.